Create a narrative

Beam Therapeutics Community

NasdaqGS:BEAM Community

1 Narratives written by author
0 Comments on narratives written by author
24 Fair Values set on narratives written by author

Create a narrative

Beam Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 15 Analysts

Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases

Key Takeaways Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential. Strategic advancements in gene editing could expand patient access and drive revenue growth through broader treatment availability.

US$47.87

FV

63.6% undervalued

2.40%

Revenue growth p.a.

0

0

24

9 days ago